How to choose between Suvotinib and Mobotinib (Mobosetinib)

Suvotinib and mobotinib (mobosetinib) are both targeted therapies for EGFR mutated non-small cell lung cancer (NSCLC), but they are different in terms of efficacy, indications and safety. When choosing, patients should make a comprehensive consideration based on their own condition, type of genetic mutation, and doctor’s advice.

Suvotinib has shown efficient anti-tumor activity in clinical trials. For example, in the WU-KONG6 study, suvotinib targeted EGFR The objective response rate (ORR) of NSCLC patients with exon 20 insertion mutations reached 59.8%, showing a good efficacy. Mobotinib has also achieved good results in relevant clinical trials, especially forEGFR For NSCLC patients with exon 20 insertion mutations, the overall response rate (ORR) can reach 28%～35% .

Both drugs are targeted at EGFR mutated NSCLC patients, but the specific indications are slightly different. Suvotinib is mainly used to treat patients with locally advanced or metastatic NSCLC who have EGFR exon 20 insertion mutations and have disease progression or intolerance after platinum-containing chemotherapy. Mobotinib has also been approved for patients with NSCLC NSCLC with EGFR exon 20 insertion mutations. When selecting, the patient's genetic mutation type and disease stage should be clarified to determine the most suitable drug.

Safety is one of the important factors to consider when choosing a drug. Suvotinib has shown good safety in clinical trials, and most common adverse reactions can be managed and recovered. The safety of mobotinib has also been verified, but the specific types and incidence of adverse reactions may be different from suvotinib. When selecting a drug, it should be evaluated based on the patient's physical condition and tolerance.

When choosing suvotinib and mobotinib, multiple aspects should be taken into consideration: first, the patient's EGFR mutation type and disease stage; secondly, the efficacy and safety data of the two drugs; and finally, the doctor's advice and the patient's personal preference. In addition, practical factors such as price and medical insurance policies may also affect patients’ choices.